Moreso F, et al. - A multicenter, prospective, randomized, placebo-controlled, double blind clinical trial was performed to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67) for the treatments for chronic antibody mediated rejection (ABMR). Data suggested that the combination of IVIG and RTX was not useful in patients displaying transplant glomerulopathy and donor-specific antibodies (DSA).